Cover Image
Market Research Report

Cytomegalovirus Retinitis Market: By Drugs (Foscarnet, Ganciclovir, Cidofovir, Fomivirsen, Others), By Route of Administration (Systemic, Ocular), By Dosage (Capsule, Implant, Solution, Tablet, and Others), By Treatment & By Region-Forecast 2019-2024

Published by IndustryARC Product code 422063
Published Content info
Delivery time: 2-3 business days
Price
Back to Top
Cytomegalovirus Retinitis Market: By Drugs (Foscarnet, Ganciclovir, Cidofovir, Fomivirsen, Others), By Route of Administration (Systemic, Ocular), By Dosage (Capsule, Implant, Solution, Tablet, and Others), By Treatment & By Region-Forecast 2019-2024
Published: December 23, 2018 Content info:
Description

Cytomegalovirus (CMV) Retinitis is caused by a herpes-type virus, cytomegalovirus infection that affects the retina of the human eye among patients having a weak immune system. Globally, growing awareness among people for different types of eye diseases, rise in the incidences of HIV infection and cytomegalovirus retinitis cases, and increasing government initiative for healthcare infrastructure and enhancement of healthcare facilities are the prime growth drivers of global biosensors market. In addition, increase in cases of Cytomegalovirus Retinitis, and emerging economies such as China, India and others, will create new opportunities for global biosensors market. However, higher cost of the research and development, risk of drug resistance, increase in anti-HIV medications, which prevent occurrence of this disease, and lack of healthcare insurance are the key restraints for global biosensors market.

This report identifies the global biosensors market size in for the year 2014-2016, and forecast of the same for year 2021. It also highlights the potential growth opportunities in the coming years, while also reviewing the market drivers, restraints, growth indicators, challenges, market dynamics, competitive landscape, and other key aspects with respect to global biosensors market.

Geographically North America dominated global biosensors market, and Asia Pacific is projected to have fastest growth, owing to rapidly increasing aging population, awareness among people for various types of eye diseases, and high prevalence rates for immunodeficiency diseases in this region. Among all the treatment, anti-CMV Oral Ganciclovir has the highest market share in global biosensors market.

This report segments global biosensors market on the basis of drugs, treatment, route of administration, dosage form, and regional market as follows:

Cytomegalovirus Retinitis Market, By Drug: Foscarnet, Ganciclovir, Cidofovir, Fomivirsen, and Others

Cytomegalovirus Retinitis Market, By Treatment: Anti-CMV Oral Ganciclovir, Anti-CMV Intravenous Drug Therapy, Anti-CMV Intraocular (local), Anti-HIV Systemic, and Retinal Detachment Through Vitrectomy

Cytomegalovirus Retinitis Market, By Route of Administration: Systemic, and Ocular

The report has focused study on biosensors market by basis of dosage form such as: Capsule, Implant, Solution, Tablet, and Others

This is report has been further segmented into major regions, which includes detailed analysis of each region such as: North America, Europe, Asia-Pacific (APAC), and Rest of the World (RoW) covering all the major country level markets in each of the region

Sample Companies Profiled in this Report are:

Bausch & Lomb Incorporated

Valeant Pharmaceuticals International, Inc.

Luitpold Pharmaceuticals, Inc.

F. Hoffman La-Roche Ltd.

Endo Pharmaceuticals, Inc.

10+

Table of Contents

Table of Contents

1. Cytomegalovirus Retinitis Market - Market Overview

2. Executive Summary

3. Market Landscape

  • 3.1. Market Share Analysis
  • 3.2. Comparative Analysis
  • 3.3. Product Benchmarking
  • 3.4. End User Profiling
  • 3.5. Top 5 Financials Analysis

4. Cytomegalovirus Retinitis Market- Market Forces

  • 4.1. Drivers
    • 4.1.1. Growing awareness among people for different types of eye diseases
    • 4.1.2. Rise in the incidences of HIV infection and cytomegalovirus retinitis cases
    • 4.1.3. Increasing government initiative for healthcare infrastructure and enhancement of healthcare facilities
  • 4.2. Restraints
    • 4.2.1. Higher cost of research and development
    • 4.2.2. Risk of drug resistance
    • 4.2.3. Increase in anti-HIV medications, which prevent occurrence of this disease
    • 4.2.4. Lack of healthcare insurance
  • 4.3. Opportunities
    • 4.3.1. Emerging economies
    • 4.3.2. Increase in cases of Cytomegalovirus Retinitis
  • 4.4. Challenges
  • 4.5. Porter's Five Forces Analysis
    • 4.5.1. Bargaining Power of Suppliers
    • 4.5.2. Bargaining Power of Buyers
    • 4.5.3. Threat of New Entrants
    • 4.5.4. Threat of Substitutes
    • 4.5.5. Degree of Competition

5. Cytomegalovirus Retinitis Market, By Drug

  • 5.1. Foscarnet
  • 5.2. Ganciclovir
  • 5.3. Cidofovir
  • 5.4. Fomivirsen
  • 5.5. Others

6. Cytomegalovirus Retinitis Market, By Treatment

  • 6.1. Anti-CMV Oral Ganciclovir
  • 6.2. Anti-CMV Intravenous Drug Therapy
  • 6.3. Anti-CMV Intraocular (local)
  • 6.4. Anti-HIV Systemic
  • 6.5. Retinal Detachment Through Vitrectomy

7. Cytomegalovirus Retinitis Market, By Route of Administration

  • 7.1. Systemic
  • 7.2. Ocular

8. Cytomegalovirus Retinitis Market, By Dosage Form

  • 8.1. Capsule
  • 8.2. Implant
  • 8.3. Solution
  • 8.4. Tablet
  • 8.5. Others

9. Cytomegalovirus Retinitis Market, By Geography

  • 9.1. Europe
    • 9.1.1. Germany
    • 9.1.2. France
    • 9.1.3. Italy
    • 9.1.4. Spain
    • 9.1.5. Russia
    • 9.1.6. U.K.
    • 9.1.7. Rest of Europe
  • 9.2. Asia Pacific
    • 9.2.1. China
    • 9.2.2. India
    • 9.2.3. Japan
    • 9.2.4. South Korea
    • 9.2.5. Rest of Asia-Pacific
  • 9.3. North America
    • 9.3.1. U.S.
    • 9.3.2. Canada
    • 9.3.3. Mexico
  • 9.4. Rest of the World (RoW)
    • 9.4.1. Brazil
    • 9.4.2. Rest of RoW

10. Cytomegalovirus Retinitis - Market Entropy

  • 10.1. Expansion
  • 10.2. Technological Developments
  • 10.3. Merger & Acquisitions, and Joint Ventures
  • 10.4. Supply- Contract

11. Company Profiles (By- Introduction, Financials, Key Insights, Key Strategy, Product Portfolio, SWOT Analysis)

  • 11.1. Bausch & Lomb Incorporated
  • 11.2. Valeant Pharmaceuticals International, Inc.
  • 11.3. Luitpold Pharmaceuticals, Inc.
  • 11.4. F. Hoffman La-Roche Ltd.
  • 11.5. Endo Pharmaceuticals, Inc.
  • 11.6. CSL Behring
  • 11.7. Emcure Pharms, Ltd.
  • 11.8. Hospira, Inc.
  • 11.9. Mylan N.V.
  • 11.10. Gilead Sciences Inc.

More than 40 Companies are profiled in this Research Report, Complete List available on Request*

"*Financials would be provided on a best efforts basis for private companies"

12. Appendix

  • 12.1. Abbreviations
  • 12.2. Sources
  • 12.3. Research Methodology
  • 12.4. Expert Insights
Back to Top